IPO and Financial Overview - Aimfinity Investment Corp. I completed its IPO on April 28, 2022, raising gross proceeds of $80.5 million from the sale of 8,050,000 units at $10.00 per unit[136]. - The company has incurred losses since inception and currently has no revenue, relying on the sale of securities and loans for funding[138]. - Following the IPO, 4,076,118 AIMA New Units, or approximately 50.9% of the total, were redeemed by shareholders[147]. - The Company has $13,671,304 held in the Trust Account, which is intended to be used for completing the Initial Business Combination[167]. - An aggregate of approximately $23,778,577 was distributed from the Trust Account to redeeming Public Shareholders, with 1,996,522 AIMA New Units submitted for redemption, representing about 64.2% of the public units[151]. - The Company incurred $5,117,607 in transaction costs related to the IPO, including $1,610,000 in underwriting fees[166]. - The underwriters received a cash underwriting discount of $0.20 per Public Unit, totaling $1,610,000 at the closing of the IPO[178]. - A deferred fee of $0.35 per Public Unit, approximately $2,817,500 in total, will be payable upon the consummation of an initial business combination[178]. Merger and Business Combination - On October 13, 2023, Aimfinity entered into a merger agreement with Docter Inc., which will result in Docter becoming a wholly owned subsidiary of the newly formed PubCo[139]. - Up to 2.5 million additional PubCo Ordinary Shares may be issued to Docter Stockholders as contingent post-closing earnout consideration based on sales performance[142]. - The merger agreement includes provisions for earnout shares contingent on sales of at least 30,000 devices in fiscal year 2024 and 40,000 devices in fiscal year 2025[144]. - The merger agreement stipulates that the board of directors of PubCo will consist of five directors, with a new composition following the business combination[143]. - The Company entered into an Exchange Agreement to convert approximately $1.5 million of outstanding promissory notes into 150,000 private units in connection with the Docter Business Combination[160]. Financial Performance and Projections - As of March 31, 2025, the Company had a working capital deficiency of $3,715,292 and cash of $4,895[173]. - For the three months ended March 31, 2025, the Company reported a net income of $64,931, with interest income of $342,182 offset by operating costs of $277,251[164]. - The Company has not generated any revenues to date and does not expect to do so until after the completion of the Initial Business Combination[163]. Compliance and Regulatory Matters - A second extraordinary general meeting was held on April 23, 2024, where shareholders approved an extension of the deadline to consummate an initial business combination to January 28, 2025[148]. - The Company has the option to extend the deadline for consummating an initial business combination up to nine times, each by an additional one-month period[146]. - The Company received a notice from Nasdaq regarding non-compliance, leading to a transfer of listing to the OTC Market effective May 5, 2025[161]. Accounting and Reporting Standards - The company is evaluating the impact of adopting ASU No. 2024-03, which requires expanded income statement expense disclosures, effective for fiscal years commencing after December 15, 2026[180]. - Management does not anticipate that recently issued accounting standards will have a material effect on the company's financial statements[181]. - The company qualifies as a smaller reporting company and is not required to provide certain market risk disclosures[182].
AIMFINITY(AIMBU) - 2025 Q1 - Quarterly Report